kth.sePublications KTH
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Integrative study of diet-induced mouse models of NAFLD identifies PPARα as a sexually dimorphic drug target
Show others and affiliations
2022 (English)In: Gut, ISSN 0017-5749, E-ISSN 1468-3288, Vol. 71, no 4, p. 807-821Article in journal (Refereed) Published
Abstract [en]

We evaluated the influence of sex on the pathophysiology of non-alcoholic fatty liver disease (NAFLD). We investigated diet-induced phenotypic responses to define sex-specific regulation between healthy liver and NAFLD to identify influential pathways in different preclinical murine models and their relevance in humans. Different models of diet-induced NAFLD (high-fat diet, choline-deficient high-fat diet, Western diet or Western diet supplemented with fructose and glucose in drinking water) were compared with a control diet in male and female mice. We performed metabolic phenotyping, including plasma biochemistry and liver histology, untargeted large-scale approaches (liver metabolome, lipidome and transcriptome), gene expression profiling and network analysis to identify sex-specific pathways in the mouse liver. The different diets induced sex-specific responses that illustrated an increased susceptibility to NAFLD in male mice. The most severe lipid accumulation and inflammation/fibrosis occurred in males receiving the high-fat diet and Western diet, respectively. Sex-biased hepatic gene signatures were identified for these different dietary challenges. The peroxisome proliferator-activated receptor α (PPARα) co-expression network was identified as sexually dimorphic, and in vivo experiments in mice demonstrated that hepatocyte PPARα determines a sex-specific response to fasting and treatment with pemafibrate, a selective PPARα agonist. Liver molecular signatures in humans also provided evidence of sexually dimorphic gene expression profiles and the sex-specific co-expression network for PPARα. These findings underscore the sex specificity of NAFLD pathophysiology in preclinical studies and identify PPARα as a pivotal, sexually dimorphic, pharmacological target. NCT02390232.

Place, publisher, year, edition, pages
BMJ Publishing Group , 2022. Vol. 71, no 4, p. 807-821
Keywords [en]
gene expression, lipid metabolism, liver metabolism, nonalcoholic steatohepatitis
National Category
Endocrinology and Diabetes
Identifiers
URN: urn:nbn:se:kth:diva-309174DOI: 10.1136/gutjnl-2020-323323ISI: 000728866100001PubMedID: 33903148Scopus ID: 2-s2.0-85104886841OAI: oai:DiVA.org:kth-309174DiVA, id: diva2:1643082
Note

QC 20220308

Available from: 2022-03-08 Created: 2022-03-08 Last updated: 2022-06-25Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records

Arif, MuhammadZhang, ChengMardinoglu, Adil

Search in DiVA

By author/editor
Arif, MuhammadZhang, ChengMardinoglu, Adil
By organisation
Science for Life Laboratory, SciLifeLabSystems Biology
In the same journal
Gut
Endocrinology and Diabetes

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 114 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf